Glaukos rises as FDA allows repeat use of glaucoma implant

Glaukos

28/01/2026 13:36

** Shares of medtech firm Glaukos GKOS.N rise 4% to $122.94 premarket

** Co says U.S. FDA now allows doctors to re-administer its "iDose TR" implant, which steadily releases glaucoma medicine to lower eye pressure

**  Glaucoma is a disease that damages the optic nerve, often due to high pressure inside the eye; the implant offers an option for patients who struggle with daily drops, per co

**  Co says updated labeling lets physicians remove the original implant and place a new one, with trials showing the approach was safe over a year

** GKOS says the device is not advised for patients with certain corneal issues or infections

** Shares down ~25% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))